





Supplementary Fig 1. Analysis of immunological marker levels in CSF for cases before and after rituximab treatment compared to healthy controls ($n=6$). All time points before treatment and after treatment are represented.



Supplementary Fig 2. Analysis of immunological marker levels in plasma for cases before and after rituximab treatment compared to healthy controls (n=50). All time points before and after treatment are represented.

Supplementary Fig 1. Analysis of immunological marker levels in CSF for cases before and after rituximab treatment compared to healthy controls (n=6). All time points before treatment and after treatment are represented.

Supplementary Fig 2. Analysis of immunological marker levels in plasma for cases before and after rituximab treatment compared to healthy controls (n=50). All time points before and after treatment are represented.